HIV Infections Clinical Trial
Official title:
NIMH Multisite HIV/STD Prevention Trial for African American Couples
This study will evaluate the effectiveness of a risk-reduction program in preventing the transmission of HIV and sexually transmitted diseases among African-American heterosexual couples, with one partner having been previously diagnosed with an HIV infection.
The transmission of sexually transmitted diseases (STDs), including HIV, is a major public
health concern, especially among minority groups in the United States. Although STDs are
prevalent across all racial and ethnic groups in the United States, the rate of STD
infection is disproportionately higher for African Americans than for white Americans.
African Americans have higher rates of HIV, chlamydia, gonorrhea, syphilis, and herpes than
white Americans. An important part of the prevention process is early education on HIV to
reduce sexual-risk behavior and to promote safe sexual practices. Interventions are needed
in a variety of settings to extensively address African Americans' risk of STDs, including
HIV. Although most HIV/STD risk-reduction interventions are conducted at the individual
level, a couple-based approach may be more effective and consistent with cultural values.
This study will compare the effectiveness of the Eban HIV/STD Risk Reduction Intervention
with the Eban Health Promotion Intervention in reducing the risk of STDs among
African-American HIV-serodiscordant heterosexual couples.
Participation in this study will last 12 months. All participants will first undergo
baseline assessments that will consist of questionnaires and biospecimen collection for STD
testing. Participants will then be assigned randomly to one of two treatment groups: the
Eban HIV/STD Risk Reduction Intervention group or the Eban Health Promotion Intervention
group. Both groups will participate in weekly 2-hour sessions over 8 weeks. The sessions
will include couple and group sessions led by trained male and female co-facilitators. The
Eban HIV/STD Risk Reduction Intervention sessions will focus on the couple and will teach
the couple about communication skills. The approach will draw upon social cognitive theory,
an ecological framework, and HIV/STD risk-reduction research with inner-city
African-American populations. The Eban Health Promotion Intervention sessions will focus on
the individual and will provide factual information on health, screening, exercise, diet
management, and medication adherence. Follow-up visits for all participants will occur at
Months 3, 6, and 12 and will include repeat baseline assessments.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |